CRISPR Archives

News and Trends 26 Oct 2017

New and Improved CRISPR: More Precise Genome Editing Now Possible

US Scientists have developed a new form of CRISPR, base editing, which can repair tiny genome segments, smaller than a single gene. Here at Labiotech, we focus on European biotech, but this was too big to miss: Researchers based at MIT and Harvard have described a new way of editing DNA and RNA — base […]

October 26, 2017 - 3 minutesmins - By Alex Dale

Eligo Bioscience Microbiome CRISPR Bacteriophage

News and Trends 26 Sep 2017

French Biotech Gets $20M to Treat the Microbiome with CRISPR Nanobots

Eligo Bioscience has announced its first fundraising round, amassing $20M (€18.5M) that will be put towards bringing it CRISPR nanobots to a first clinical trial in humans. The French startup Eligo Bioscience has grown rapidly since its foundation in 2014. The company has announced today its Series A round, which, led by Khosla Ventures and […]

September 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Aug 2017

Designer Babies in Europe: German Merck Set to Receive CRISPR Patent

Merck KGaA has received a Notice of Intention to Grant from the European Patent Office that its CRISPR patent will cover genomic integration. Everyone in biotech is gunning for a piece of the CRISPR pie, and German Merck will likely become the next company to acquire IP, adding to the pile it began building in 2012. […]

August 3, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 17 Jul 2017

A Brand New Outlook on Induced Pluripotent Stem Cells

In an exclusive interview with Dr David Hallett, we discover why iPS cells are the perfect replacement for human embryonic stem cells, what is so unique about them and the challenges researchers face in the field! Talk of using human stem cells to better understand and even cure diseases has been around for a few decades. […]

July 17, 2017 - 8 minutesmins - By External Contributor

News and Trends 3 Jul 2017

From Rockets to DNA – From SpaceX to CRISPR

With CRISPR being one of the most significant discoveries in genome engineering history, many scientists are now turning towards it as a basic foundation of their research. In response, companies are developing new technologies and products designed to help these very scientists become more effective in their research. One such company is Silicon Valley entity […]

July 3, 2017 - 6 minutesmins - By External Contributor

In Depth 13 Jun 2017

Will Gene Editing Bypass the GMO Struggle or Worsen Public Distrust?

In the US, the first CRISPR-edited crops were able to bypass GMO regulations, but Europe’s plant scientists are still awaiting the final go ahead. In April 2016, the US Department of Agriculture (USDA) gave the green light to the first CRISPR-edited crops, a mushroom that has been engineered to resist browning and a waxy corn from […]

June 13, 2017 - 6 minutesmins - By Melanie De Almeida

trust me im an artist amsterdam bioart exhibition

News and Trends 27 May 2017

“Trust me, I’m an Artist” Explores the Ethics of Biotech in Amsterdam

The exhibition in Amsterdam showcases the works of ten bioartists questioning the huge complexity of ethics in the rapidly developing field of biotechnology. The Waag Society has brought together bioartists from all over Europe that explore topics like gene editing, antibiotics, human tissue culture, public health and personalized medicine. After a series of performances discussed […]

May 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Apr 2017

Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance

Anna Dumitriu’s latest bioart piece is a historic dress carrying bacteria genetically modified using CRISPR and opens the debate on antibiotic resistance. A wartime women’s suit is the canvas where Anna Dumitriu paints the history of antibiotics. The holes and stains in the suit are patched and embroidered with silk that has been dyed with E. […]

April 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

European Patent Office CRISPR Decision 1

News and Trends 28 Mar 2017

Europe Turns the Tables in the CRISPR Patent Battle

ERS Genomics has announced that the EPO intends to grant a patent with broad claims covering the use of CRISPR to Emmanuelle Charpentier. ERS Genomics has announced that the European Patent Office (EPO) will grant its founder, Emmanuelle Charpentier as well as the University of Vienna and University of California, Berkeley, a patent covering the broad use of CRISPR-Cas9 […]

March 28, 2017 - 3 minutesmins - By Melanie De Almeida

Allergan Editas Medicine CRISPR eye disease

News and Trends 15 Mar 2017

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development alliance with the American Editas Medicine, which is on the side of […]

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Feb 2017

The Patent Office has Spoken: What does it Mean for CRISPR in Europe?

The US Patent Office has ruled that the Broad Institute’s CRISPR patents do not interfere with those from UC Berkeley. While this might sound like everybody wins, it’s actually a loss for Charpentier and the CRISPR Therapeutics team. CRISPR has been hailed as the ‘scientific discovery of the century’. This molecular technique could be used […]

February 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2017

The UK Steps Up its Game in Automated CRISPR Gene Editing

Horizon Discovery now has full access to CRISPR technology and will develop an automated gene editing platform in collaboration with Solentim. Horizon Discovery, based in Cambridge, UK, uses gene editing technology to create custom cell lines for research. To step up its game, the company has upgraded its existing license with ERS Genomics‘ to obtain […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us